Top news of the week: 18.02.2021.
Startups
Moncef Slaoui, departing Warp Speed, raises $250 million to test his R&D philosophy in a new company
The goal is to combine the focus of a small biotech with the balance sheet, access to money, and negotiating clout a larger firm has.
The top 10 biotech IPOs of 2020
The class of 2020 biotech IPOs will go down as one of the most buoyant in history, with the leading 10 raising a massive $3.19 billion collectively.
Pfizer, Verily-backed Alzheimer's biotech Cortexyme hit by FDA partial hold over liver toxicity
As it looks for a new way to treat Alzheimer’s and clear a near 20-year backlog of failed R&D for the memory-wasting disease, big-name-backed biotech Cortexyme has hit a snag.
GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19
Last year, Big Pharma GlaxoSmithKline and George Scangos’ biotech Vir joined forces against COVID-19. Now, the pair is turning its crosshairs on a broader range of respiratory diseases.
Small Business Strikes Back: The Numbers Behind The Next 1000
It’s a critical moment for small business USA—blindsided by Covid, it remains our most powerful and reliable economic engine and field of dreams.
Mintz Partners with Massachusetts Life Sciences Center to Support Women Entrepreneurs through Massachusetts Next Generation Initiative
Firm provides funds, ‘essential’ coaching sessions to support women entrepreneurs in early-stage life sciences companies Mintz is proud to partner with the Massachusetts Life …
The coronavirus will stick around forever
These are the top stories written by Business Insider's healthcare team for the week ending February 12.
Chutes & Ladders—After Verastem pit stop, bluebird vet Neumann lands at Kite
Ex-bluebird cancer research chief Frank Neumann lands at Gilead's Kite Pharma after a brief stopover at Verastem. Hot on the heels of fresh CEO grab, Penrose TherapeuTx signs new chief ...